Brief: Sirnaomics Receives IND Clearance From FDA For Phase I Clinical Study Of RNAI Therapeutic
12/04/2023 02:18
April 12 (Reuters) - Sirnaomics Ltd 2257.HK :
* RECEIVES IND CLEARANCE FROM U.S. FDA FOR- PHASE I CLINICAL
STUDY
OF RNAI THERAPEUTIC STP122G
Source text for Eikon: ID:
Further company coverage: 2257.HK
Recent news on Sirnaomics
See all newsBrief: Sirnaomics To Issue 2.4 Million New Shares At Hk$4.69 Each Under General Mandate
Brief: Sirnaomics Says Chairman Purchases 38,000 Shares At Average Price Hk$5.93 Per Share
Brief: Sirnaomics Ltd To Issue 17.4 Million Subscription Shares
Brief: Sirnaomics Says Poon Hung Fai Appointed As Chairman
Brief: Sirnaomics Posts FY Net Income USD -50.2 Million